Login to Your Account



Other News To Note


Tuesday, June 21, 2011
Prometheus Laboratories Inc., of San Diego, will defend its method patents in the Supreme Court for calibrating the proper dosage of thiopurine drugs used to treat autoimmune diseases. The court agreed Monday to hear Mayo Collective Services v. Prometheus Laboratories Inc. The first time the case came before the high court, the justices sent it back to the U.S. Court of Appeals for the Federal Circuit with instructions to reconsider it in light of the Bilski v. Kappos ruling. The Federal Circuit maintained that Prometheus' personalized medicine-type claims are patent-eligible.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription